SG Americas Securities LLC Buys New Position in AtriCure, Inc. (NASDAQ:ATRC)

SG Americas Securities LLC purchased a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 17,393 shares of the medical device company's stock, valued at approximately $488,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Comerica Bank raised its position in shares of AtriCure by 70.5% during the first quarter. Comerica Bank now owns 2,522 shares of the medical device company's stock worth $77,000 after purchasing an additional 1,043 shares during the period. Quest Partners LLC lifted its stake in shares of AtriCure by 38.3% in the second quarter. Quest Partners LLC now owns 5,868 shares of the medical device company's stock valued at $134,000 after buying an additional 1,626 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of AtriCure during the fourth quarter valued at about $213,000. Mount Yale Investment Advisors LLC increased its position in shares of AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company's stock worth $222,000 after acquiring an additional 2,368 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in shares of AtriCure by 8.5% during the first quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company's stock worth $255,000 after acquiring an additional 659 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Insider Activity at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $24.07, for a total transaction of $84,245.00. Following the sale, the director now owns 8,970 shares in the company, valued at $215,907.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ATRC has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price target on AtriCure from $34.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Needham & Company LLC decreased their price target on AtriCure from $40.00 to $34.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Piper Sandler dropped their price objective on AtriCure from $65.00 to $40.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 31st. Stifel Nicolaus cut their price target on shares of AtriCure from $30.00 to $26.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Finally, StockNews.com raised AtriCure from a "sell" rating to a "hold" rating in a research report on Saturday, September 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, AtriCure has an average rating of "Moderate Buy" and a consensus price target of $42.44.

AtriCure Stock Performance

Shares of ATRC stock traded down $0.59 on Thursday, hitting $28.57. 422,805 shares of the stock were exchanged, compared to its average volume of 727,784. The firm's 50 day moving average is $26.38 and its two-hundred day moving average is $24.17. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.00. The firm has a market capitalization of $1.36 billion, a PE ratio of -36.45 and a beta of 1.44. The company has a current ratio of 4.13, a quick ratio of 2.93 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.17). AtriCure had a negative net margin of 9.33% and a negative return on equity of 8.39%. The firm had revenue of $116.27 million during the quarter, compared to analyst estimates of $116.24 million. During the same quarter last year, the business earned ($0.12) earnings per share. The company's quarterly revenue was up 15.2% on a year-over-year basis. Sell-side analysts expect that AtriCure, Inc. will post -0.77 earnings per share for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.